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Abstract 
Background: Anticonvulsant hypersensitivity syndrome represents a rare but potentially fatal kind of adverse drug 
reaction. This clinical picture often hampers the flexibility with which alternative anticonvulsants or even other classes 
of drugs are prescribed in these patients, negatively affecting the efficacy of treatment and the course of the disease. 
The aim of this study was to analyse a group of six patients with severe cutaneous drug reactions induced by anticon-
vulsants and to report which alternative antiepileptic drugs and which drugs of other classes were tolerated.
Case presentation: A total of six patients (2 males and 4 females, age 11–73 years) are described in this study. In 
all the patients the onset of the severe cutaneous drug reactions was 2–4 weeks after initiating the anticonvulsant 
therapy: 2 out of 6 patients presented with a drug reaction with eosinophilia and systemic symptoms under therapy 
with phenytoin; 2 out of 6 presented with Stevens–Johnson syndrome under therapy with lamotrigine; and 2 out of 
6 presented with a toxic epidermal necrolysis, one of them under therapy with valproic acid, and the other one under 
therapy with lamotrigine. Alternative anticonvulsants tolerated after the reaction were: clonazepam, levetiracetam, 
diazepam, delorazepam and lormetazepam.
Conclusions: In our cases we observed that non aromatic anticonvulsants and benzodiazepines were well tolerated 
as alternative treatments in six patients with reactions to aromatic anticonvulsivants and that the risk of hypersensitiv-
ity reactions to other drug classes was not increased as compared to general population.
Keywords: Anticonvulsants, Drug hypersensitivity, Anticonvulsant hypersensitivity syndrome, Stevens–Johnson 
syndrome, Toxic epidermal necrolysis, Drug reaction with eosinophilia and systemic symptoms, Severe cutaneous 
adverse reactions
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Background
Anticonvulsant hypersensitivity syndrome (AHS) rep-
resents a rare but potentially fatal kind of adverse drug 
reaction. The antiepileptic drugs (AEDs) most commonly 
involved are the aromatic anticonvulsants such as phe-
nytoin, phenobarbital, carbamazepine, and lamotrigine; 
however, in the literature several cases induced by valp-
roic acid are also reported [1–3]. Clinical presentations 
are highly variable and include either simple pruritic 
eruptions or severe forms such as Stevens–Johnson 
syndrome (SJS), toxic epidermal necrolysis (TEN) and 
drug reaction with eosinophilia and systemic symp-
toms (DRESS) [4, 5]. SJS and TEN are characterized by 
detachment of the epidermis and erosions of mucous 
membranes and are considered to be the same disease, 
the only difference being the extent of skin detach-
ment, < 10% of total body surface area in SJS, and > 30% 
in TEN [6]. DRESS is characterized by eosinophilia, skin 
rash, fever, lymphadenopathy, and visceral organ involve-
ment [7]. The clinical symptoms usually develop from 1 
to 8 weeks after starting the antiepileptic therapy; adults 
older than 64  years are at the highest risk for severe 
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cutaneous adverse reactions (SCARs) [8]. The estimated 
incidence of mucocutaneous severe reactions to AEDs 
with internal organ involvement ranges from 1 in 1000 
to 1 in 10,000 drug exposures [9]. In SJS/TEN necrosis 
of the skin and mucous membranes characterizes the 
disease; apoptosis of keratinocytes is mediated by the 
Fas–FasL interaction or through cytotoxic T-cell release 
of granulysin [10]. A genetic background confers an 
increased risk to develop severe forms of AHS in some 
ethnic groups, as demonstrated by several associations 
between HLA-A and -B haplotypes and severe anticon-
vulsant reactions, as reported in Table 1 [11–16].
As it has been demonstrated in the last decade, the T 
cell activation at the basis of SCARs is explainable by the 
so called “p-i mechanism” that does not imply any pro-
cessing or metabolism of the drug, making thus reason-
able a definite HLA restriction [17].
Infections play an important role in the pathogenesis of 
these reactions through an aspecific activation of immu-
nological response, so that, for example the human her-
pes virus 6 (HHV-6) reactivation in DRESS is considered 
a relevant diagnostic marker [18]. Moreover, viral infec-
tions as well as other cell damaging events such surgery 
or severe cardiac diseases, represent the so called ‘dan-
ger’ factors able to prepare the pathogenetic background 
favouring the appearance of SCARs. All these aspects are 
crucial points to address in order to evaluate the risk of 
hypersensitivity reactions to alternative anticonvulsants 
or other types of drug. However, more studies will be nec-
essary to better define the kind of genetic/environmental 
interaction that are at the basis of these syndromes. As 
a result, SCARs often restrict the use of alternative anti-
convulsants or of other classes of drugs that have to be 
prescribed in these patients, negatively affecting the effi-
cacy of treatment and the course of the disease.
The aim of this study was to describe a group of six 
patients with SCARs induced by anticonvulsant drugs 
and to report which alternative antiepileptic drugs and 
drugs of other classes were tolerated.
Case reports
A total of 6 caucasian patients (2 males and 4 females, 
age 11–73  years), admitted to Niguarda Ca’ Granda 
Metropolitan Hospital for SCARs, are described in this 
study. In all of the patients the onset of the SCARs was 
2–4  weeks after initiating the anticonvulsant therapy. 
For each patient we collected data regarding medical and 
pharmacological history. They were evaluated according 
to the diagnostic criteria based on RegiSCAR (Registry 
for Serious Cutaneous Reactions) classification (i.e. both 
clinical and histological features). In order to identify 
the inducing drug, we obtained a detailed and thorough 
medication history. Furthermore, a standard set of labo-
ratory tests was performed including blood count, renal 
function, liver function, inflammatory markers, lactate 
dehydrogenase (LDH). Moreover, samples for antinuclear 
antibodies (ANA), and immunoglobulins against HHV-
6, hepatitis virus B (HBV) and C (HCV), herpes simplex 
virus (HSV) type 1 and 2, human immunodeficiency virus 
(HIV), Epstein–Barr virus (EBV), and cytomegalovirus 
(CMV), blood cultures and urine cultures, were collected 
in order to exclude other diseases. Among the six cases, 
we found two cases of DRESS, two cases of SJS, and two 
cases of TEN. Tables 2 and 3 summarize the clinical char-
acteristics of the study patients. Table 4 shows treatment, 
culprit and tolerated drugs after and during SCARs.
Cases of DRESS
Two patients, an 11-year old male (P1) and a 32-year old 
female (P2) presented SCARs and relevant eosinophilia 
after 3  weeks of therapy with phenytoin, prescribed as 
prophylactic anticonvulsant for surgical removal of glio-
blastoma in P1 and neurosurgery due to the rupture of 
a middle cerebral artery aneurysm in P2. Both patients 
developed generalized papular rash, fever, asthenia, 
lymphadenopathy, leukocytosis, eosinophilia, and signs 
Table 1 Associations between HLA-A and -B haplotypes and severe anticonvulsant reactions
SJS: Stevens Johnson syndrome, TEN: toxic epidermal necrolysis, DRESS: drug reaction with eosinophilia and systemic symptoms
Disease Culprit drug HLA haplotype Population Authors (ref. number)
SJS ⁄TEN Carbamazepine HLA-B*15:02 Asians [11–13]
SJS/TEN and DRESS Carbamazepine HLA-A*31:01 Europeans [14, 15]
SJS/TEN and DRESS Phenytoin HLA-B*15:13 and -B*15:02 Malaysians [16]
Table 2 Demographics and risk factors
Patient Sex/age Risk factors
P1 M/11 Surgery treatment of cerebral cancer
P2 F/32 Surgery for rupture of middle cerebral artery 
aneurysm
P3 M/73 Severe cachexia
P4 F/53 Acute disseminated encephalomyelitis
P5 F/41 Head trauma
P6 F/21 None
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of liver damage, as reported in Table  3. Eosinophilia, 
lymphadenopathy, skin biopsy in P1, and HHV-6 DNA 
positivity confirmed the diagnosis of DRESS. Other 
diagnostic tests were carried out to better characterize 
the extent of the organ involvement and possible com-
plications. Abdominal ultrasound showed splenomegaly 
in P1 and was normal in P2. Positron emission tomog-
raphy-computed tomography and cervical lymph node 
biopsy performed to investigate the relevant lymphoad-
enomegaly in P2 demonstrated only reactive lymphad-
enopathy, thus excluding a lymphoproliferative disorder. 
Anticonvulsants were discontinued in both the patients 
after the diagnosis and a treatment with methylpredni-
solone 40 mg daily for 40 days was given to P1; a com-
plete and stable remission of symptoms was observed 
after a slow tapering of methylprednisolone over a 
period of 2  months. P2 underwent therapy with pred-
nisone 70 mg daily for 10 days; glucocorticoid was then 
interrupted for a few days in order to perform lymph 
nodal biopsy that confirmed the reactive lymphadenopa-
thy: a severe clinical relapse was observed characterized 
by macular papular rash, systemic lymphadenopathy, 
itching and asthenia. Prednisone was readministered at a 
dosage of 50 mg daily for 15 days, reduced to 25 mg and 
slowly tapered off 5 mg every 2 weeks under strict medi-
cal control. Normalization of inflammatory and necro-
sis markers was observed in P2 after 4 months from the 
beginning of glucocorticoid therapy; subsequently P2 
showed relevant adverse effects: hypertension, headache, 
acne, hair loss and osteoporosis. In both cases a new 
anticonvulsant drug was necessary for a relapse of sei-
zures. In P1 clonazepam was introduced after few days 
of glucocorticoid premedication treatment and was well 
tolerated in the following months. P2 underwent treat-
ment with levetiracetam for seizure relapse and the drug 
was well tolerated in the following months. Other drugs 
were well tolerated after the reaction despite the fear of 
clinical relapse, such as ibuprofen and clarithromycin in 
P1; metamizole, tramadol, amoxicillin, clarithromycin, 
ketoprofen, lercanidipine, and metoclopramide in P2. 
One month after definitive suspension of glucocorticoids 
P2 manifested an abrupt increase in blood pressure, dys-
arthria, confusional state and headache not responsive 
to treatment. The patient was again hospitalized and 
the following blood values were observed: Hb 7.8 g/dL, 
platelets count 11,000 × 109/L, LDH 1560 IU/L, hapto-
globin 10 mg/dL, the presence of schistocytes in periph-
eral blood, total bilirubin 2.2  mg/dL, and ADAMTS13 
activity at 7%. After hospital admission the patient 
manifested purpuric lesions. Brain magnetic resonance 
imaging was carried out and showed micro hemor-
rhages. The diagnosis of thrombotic thrombocytopenic 
purpura (Moskowitz syndrome) was made so treatment 
with rituximab at dose of 375  mg/m2, i.e. once weekly 
for 4 weeks plus prednisone at 50 mg daily for 2 weeks 
with tapering after 1  month was instituted. The com-
plete resolution of the clinical picture required a total of 
14 months.
Table 4 Treatment, culprit and tolerated drugs after and during SCARs
SCARs: severe cutaneous adverse reactions, SJS: Stevens–Johnson syndrome, DRESS: drug reaction with eosinophilia and systemic symptoms, TEN: toxic epidermal 
necrolysis
Patient SCARs Culprit drug Latency (weeks) Treatment Tolerated anticonvulsants Other tolerated drugs
P1 DRESS Phenytoin 3 Methylprednisolone for 
3 months
Clonazepam Ibuprofen, clarithromycin
P2 DRESS Phenytoin 3 Prednisone for 1 year Levetiracetam Metamizole, tramadol, 
amoxicillin, clarithromycin, 
ketoprofen, metoclopramide, 
rituximab, lercanidipine
P3 SJS Lamotrigine 4 Hydrocortisone bolus, 
prednisone for 1 month and 
immunoglobulin intrave-
nously
Delorazepam and lormetaz-
epam
Echinocandin
P4 SJS Phenytoin 4 Hydrocortisone bolus, 
prednisone for 1 month and 
immunoglobulin intrave-
nously
Diazepam Teicoplanin, haloperidol
P5 TEN Valproic acid 2 Prednisone for 1 month and 
immunoglobulin intrave-
nously
Diazepam and levetiracetam Meropenem
P6 TEN Lamotrigine 2 Prednisone for 1 month and 
immunoglobulin intrave-
nously
Diazepam and levetiracetam Teicoplanin
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Cases of SJS
Two patients, a 73-year old male (P3) and a 53-year old 
female (P4) presented SCARs after 4  weeks of therapy 
with lamotrigine, prescribed to P3 for bipolar disorder 
with prevailing depressive symptoms in severe cachexia, 
and phenytoin prescribed to P4 as prophylaxis after acute 
disseminated encephalomyelitis. Both had developed 
diffuse maculopapular rash, fever, and 24 h later ulcera-
tions of the oral mucosa, blistering skin lesions, epithe-
lial detachment, conjunctivitis, and diffuse pain. HSV-2 
IgM positivity was observed in P3. The clinical pictures 
and skin biopsy performed in P4 confirmed the diagnosis 
of SJS (Table 3). Abdominal ultrasound, echocardiogram 
and chest CT excluded organ involvement. After sus-
pected SJS diagnosis, anticonvulsants were immediately 
discontinued; both P3 and P4 were treated with hydro-
cortisone 1 g bolus, followed by prednisone 50 mg/daily 
for 10 days tapered in the subsequent month. During the 
hospitalization the patients were treated with intrave-
nous immunoglobulins (IV Ig) 0.4 g/kg daily for 5 days, 
and with topical agents. Enteral feeding and crystalloid 
were also required. New anticonvulsants were given: 
lormetazepam and diazepam in P3 and diazepam in P4. 
Moreover, P4 developed psychosis as an adverse effect 
of glucocorticoid therapy and was treated with haloperi-
dol. Echinocandin and teicoplanin were administered for 
2  weeks because of prolonged fever and positive blood 
cultures for Candida albicans and methicillin-resistant 
Staphylococcus aureus (MRSA) in P3 and P4, respec-
tively. Both antibiotics were well tolerated by the patients 
and they were discharged after 3 weeks in good clinical 
conditions.
Cases of TEN
Two females, 41  year old (P5), and 21  year old (P6), 
presented SCARs after 2  weeks of therapy with valp-
roic acid, given to P5 consequently to head trauma, and 
with lamotrigine, used in P6 for epilepsy. Both patients 
developed diffuse maculopapular rash and in addition P6 
showed severe asthenia and conjunctivitis. Their clinical 
pictures progressed rapidly to TEN, showing epidermal 
detachment, mucosal involvement with severe bleeding 
requiring blood transfusions. In particular, epidermal 
detachment involved 45 and 95% of the body surface 
in P5 and P6, respectively. During the hospitalization, 
P6 developed respiratory distress requiring mechanical 
ventilation. Diagnostic routine work up on the diagnosis 
showed leukocytosis and sign of liver damage in both the 
patients. Infections were detected by urine cultures that 
showed Enterococcus faecalis in P5 and by blood cul-
tures that were positive for Staphylococcus capitis and 
MRSA in P5 and in P6, respectively. Clinical pictures 
and skin biopsy confirmed the TEN diagnosis (Table 3). 
Ultrasound abdomen showed hepatomegaly in both 
patients, and echocardiograms were normal. Based on 
the diagnosis of TEN, anticonvulsants were stopped and 
the patients were treated with topical medications, IV Ig 
at 0.4/kg daily for 5 days and with prednisone 50 mg daily 
during 2  weeks of the hospitalization with slow taper-
ing with complete remission after 1 month from the dis-
charge. Meropenem and teicoplanin were administered 
for 2  weeks to treat secondary infections in P5 and P6 
respectively and enteral feeding and crystalloid were also 
required. Antibiotics were perfectly tolerated also after 
glucocorticoid tapering. In both cases, new anticonvul-
sant were considered necessary and levetiracetam and 
diazepam were introduced in P5 and P6 respectively, a 
few days after the start of cortisone treatment, and were 
well tolerated in the following months.
Conclusions
The principal aim of this study was to describe the 
course of six patients affected by SCARs to anticon-
vulsants. These drugs, as well as allopurinol, have been 
already regarded as one of the most common causes of 
SCARs [19, 20]. The analysis of our clinical data allowed 
us to determine the tolerance to alternative anticon-
vulsants and to different drug classes that in the rou-
tine practice are often not administered for the fear of 
a relapse. According to a prospective RegiSCAR study, 
aromatic AEDs, in particular carbamazepine, pheny-
toin, and lamotrigine, were considered responsible 
for the reaction in the 35% of cases. Additional culprit 
drugs were allopurinol, sulfonamides and other anti-
biotics involved in another 41% of cases [19]. Two out 
of 6 SCARs from our study were induced by lamotrig-
ine, three by phenytoin and one by valproic acid. In a 
recent review 172 cases of DRESS associated with 44 
drugs were analyzed: the most frequently implicated 
was carbamazepine, followed by lamotrigine and phe-
nytoin [21]. In SJS/TEN, an association with 12 “highly 
suspect” medication was reported that included anti-
convulsants, mostly carbamazepine, oxcarbazepine, 
phenytoin and lamotrigine [20]. These observations 
confirmed previous clinical data [22, 23]. The reac-
tions in our patients occurred on the first exposure to 
the drug, with a latency time from 2 to 4 weeks after the 
beginning of therapy, as already observed [1, 9]. Sev-
eral potential risk factors for AED hypersensitivity were 
reported: previous history of AED-induced eruption 
[24], autoimmune diseases, treatment with corticoster-
oids, family history of SCARs [25], age below 12  years 
or above 64 associated with altered drug metabolism 
[8], head injury, surgery, genetic markers such as HLA-
B*15:02 and HLA-A*31:01, and reactivation of HHV-6 
and -7, EBV and CMV virus [26, 27].
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In our patients we identified several of the above 
quoted risk factors, in particular: surgery (P1, P2), head 
trauma (P5), and herpes viral infections in P1, P2 (i.e. 
HHV-6), and in P3 (i.e. HSV 2); of note, this last patient 
also suffered from recurrent airway infections due to a 
cachectic state. All these situations have been reported 
to potentially determine severe distress and injury to cells 
that in turn can release internal molecules able to act as 
damage or danger signals stimulating toll-like receptors 
on antigen presenting cells activating thus the immune 
response.
The culprit drugs were identified only by clinical data 
as up to now no standardized diagnostic test has been 
adopted in delayed T-cell mediated drug allergy reac-
tions except in contact dermatitis IVa type [28]. Although 
different skin tests (SPT, ID, patch tests) have been sug-
gested as useful tools for the diagnosis of SCARs [29], 
more recently drug patch test was reported as the only 
convenient and safe tool for identifying culprit drugs in 
DRESS; on the contrary, this procedure was not recom-
mended in SJS/TEN [30, 31]. We did not perform in vivo 
tests because our patients assumed only AEDs at the 
onset of SCARs. The clinical course worsened after dis-
continuation of the culprit drug, as already reported in 
DRESS [32]. Liver was the extracutaneous organ more 
frequently affected in our patients, as usually observed 
in DRESS (70–95%), and in SJS/TEN [33]. In DRESS, 
hepatic damage was more severe after phenytoin [34], 
as observed also in our two DRESS patients (P1 and P2). 
We observed no heart or kidney damage. Signs of renal 
damage were reported just in the 11% of DRESS patients, 
mainly, after allopurinol administration [19]. In P1 and 
P2, a diffuse lymphadenopathy was observed, as already 
reported in DRESS in nearly 75% of the cases [35]. In par-
ticular, in P2 lymph node biopsy showed a benign lym-
phoid hyperplasia, one of the two histological patterns 
reported in this syndrome, besides pseudolymphoma 
[7]. The most common complications we observed were 
secondary infections i.e. septicemia (4 out of 6 patients; 
66%). A transient respiratory failure appeared in one 
case (P6). P2 developed an autoimmune disease, a seque-
lae already reported in DRESS especially if not treated 
with steroids [36]. However, in our patient a thrombotic 
thrombocytopenic purpura (Moskowitz syndrome) was 
developed nevertheless a previous high dose steroid ther-
apy followed for several months. The time for complete 
resolution of the hypersensitivity reaction ranged from 
2 to 12  months, compared to a period of 14–345  days 
reported by others [19, 36].
In respect to the culprit drugs, 5 out of 6 SCARs cases 
were induced by aromatic anticonvulsant drugs to con-
firm an increased risk of severe reactions to these mol-
ecules in comparison with other AEDs. In two cases (P3 
and P6) the culprit drug was lamotrigine, a molecule 
already associated with a high risk of SJS and TEN [23], 
through a dose dependent effect [37]. Both lamotrig-
ine and phenytoin, culprit drugs in P3, P4 and P6, were 
regarded as “highly suspect” compounds associated with 
SJS/TEN in a pharmacovigilance study [20]. Cross-reac-
tivity between aromatic anticonvulsants ranged from 30 
to 58% [38, 39], for this reason in our cases we selected 
non aromatic drugs, i.e. benzodiazepines and leveti-
racetam, as an alternative treatment. This choice relied 
on previous reports suggesting non aromatic AEDs, like 
gabapentin, as agents with low allergenic potential [39], 
in particular levetiracetam, was a drug associated with 
lower rash rates (0–6%) [24].
Some authors advised against treatment with antibi-
otics or NSAIDs in the DRESS acute period, for unex-
plained cross-reactivity able to worsen the clinical 
picture [27]. However, alternative antimicrobials were 
administered without adverse effects in 16 out of 17 
patients affected with antibiotic-related DRESS [40]. Our 
experience showed that in AED-induced SCARs the risk 
of hypersensitivity reactions to other drug classes was 
not increased in comparison with general population. 
Recently, a strict relationship between SCARs induced by 
allopurinol and carbamazepine and definite HLA-aplo-
types has been identified. This observation might impli-
cate a tight HLA restriction also in adverse reactions to 
different drugs and consequently a low risk of additional 
events [41]. In fact, other drugs tolerated were: ibupro-
fen, clarithromycin, amoxicillin, metamizole, tramadol, 
ketoprofen, metoclopramide, rituximab, lercanidipine, 
echinocandin, teicoplanin, haloperidoland meropenem. 
In our patients, we discontinued the culprit drug and 
administered steroid therapy at high dosage, a treatment 
suggested in other studies [42, 43]. High doses of steroid 
might have an immunosuppressive effect preventing a 
relapse due to other compounds [41]. The management 
of our patients differed according to the Unit in which 
they were admitted: DRESS subjects were treated in our 
Centre with high doses of steroids, while SJS/TEN sub-
jects were treated in Burn Unit with IVIG, steroids and 
topic therapy. High doses of IVIG was effective in our 
SJS/TEN patients, as already reported in some stud-
ies [44], although this treatment was considered useless 
by other Authors [45]. The prognosis was good also as a 
consequence of careful supportive treatment conducted 
in specialized Burn Units.
In conclusion, on the basis of our case reports, we can 
suggest that non aromatic drugs, i.e. benzodiazepines 
and levetiracetam, are the most safe alternative treat-
ment in SCARs due to the anticonvulsants. Moreover, we 
observed that drugs belonging to other classes were well 
tolerated in these patients confirming thus indirectly an 
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HLA restriction for hypersensitivity reactions to other 
anticonvulsant drugs as well as to carbamazepine and 
phenytoin.
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